Uncategorized
Oxetane as a Strategic Bioisostere: Improving ADMET Profiles and Pharmacokinetics in Small Molecule Design
Oxetane as a Strategic Bioisostere. Oxetane Motif in Medicinal Chemistry
In medicinal chemistry, bioisosteres serve as indispensable structural guides for structure-activity relationship (SAR) exploration and lead optimization. By substituting chemical groups with structural analogues that mimic their physicochemical properties, researchers can systematically enhance drug efficacy, fine-tune selectivity, optimize ADMET profiles, minimize off-target toxicity, and establish novel intellectual property.
Among these structural tools, the oxetane ring has emerged as an exceptionally attractive motif. Both van der Waals volume calculations and experimental structural data demonstrate that an oxetane group occupies a spatial volume closely mimicking that of a gem-dimethyl group. (Figure 1)
Beyond the spatial properties common to four-membered heterocycles, the highly electronegative oxygen atom endows oxetanes with a potent inductive electron-withdrawing effect. This effect propagates efficiently through the σ-bonding. Famously highlighted by Carreira and colleagues, introducing an oxetane α to a primary or secondary amine dramatically reduces its pKa by roughly 2.7 units (rendering the nitrogen approximately 500-fold less basic, shifting pKa from 9.9 down to 7.2). This precise modulation can fundamentally alter a molecule’s pharmacokinetic profile.
Figure 1. Impact of oxetane motif on physiochemical properties of molecules
Oxetane in Small molecule Drugs
Figure 2. Examples of Oxetanes in FDA-approved and Investigational Drugs
The structural landscape of FDA-approved, oxetane-containing therapeutics generally spans three distinct categories:
- The Taxane Family (Natural Products & Semisynthetics)
- Metabolic Inhibitors
- Fully Synthetic Small Molecules (Modern Medicinal Chemistry)
Additionally, multiple pipeline candidates featuring synthetic oxetane rings—such as Pfizer’s Danuglipron (GLP-1 receptor agonist for diabetes/obesity) and Roche/Ark Biopharma’s RSV inhibitor Ziresovir—have advanced deep into late-stage clinical trials.
Ziresovir: A Case of Oxetane in Discovery Campaign
Ziresovir (RO-0529/AK0529) is a potent, selective respiratory syncytial virus (RSV) fusion protein inhibitor. Originally discovered by Roche and licensed to Ark Biosciences in 2014, its optimization timeline provides a textbook example of utilizing oxetane properties to address severe downstream drug development hurdles.
During early structure-activity exploration starting from hit compound 1, researchers systematically modified the fused ring architecture linking the quinoline core. The conformation of the scaffold significantly impacted anti-RSV activity, driven largely by the dihedral angle between the two planes: The initial 5-membered ring analogues adopted a near-planar conformation that yielded sub-optimal binding. The 6-membered ring system with 40° skew and 7-membered compound 2 with 90° both exhibited target potency with the increasing three-dimensionality.
However, increasing potency was only half the battle. The core milestone of the discovery campaign was the late-stage installation of the oxetane moiety on the terminal amine. The primary objective was to deliberately attenuate the basicity of this nitrogen atom via the oxygen’s inductive effect. Lowering the pKa successfully reduced the compound’s volume of distribution (Vss), preventing undesired, excessive accumulation in tissues and mitigating potential toxicity risks.
Ultimately, docking models confirmed that the oxetane ring in ziresovir functions primarily as a master structural controller for conformation and basicity, rather than acting as a direct hydrogen-bonding partner with the target protein—a perfect showcase of bioisosteric engineering.
